Antimicrobial Agents and Chemotherapy
Antimicrobial Agents and Chemotherapy
3 years ago

The alternative sigma factors SigE and SigB are involved in tolerance and persistence to antitubercular drugs.

Palù, Provvedi, Barrios Payan, Mata Espinosa, Manganelli, Boldrin, Hernandez-Pando, Pisu
Emergence and spread of drug resistant Mycobacterium tuberculosis strains threatens our ability the possibility to treat this disease in the future. Even if two new antitubercular drugs were recently introduced, there is still the need to design new molecules whose mechanism of action could reduce treatment length. We showed that two alternative sigma factors of M. tuberculosis (SigE and SigB) have a major role in determining the level of basal resistance to several drugs and the amount of persisters surviving long drug treatment. We also demonstrate that ethambutol, a bacteriostatic drug is highly bactericidal for M. tuberculosis mutants missing either SigE or SigB. We suggest that developing molecules able to interfere with their activity could not only reduce M. tuberculosis virulence in vivo, but also boost the effect of other drugs by increasing its sensitivity and reducing the number of persisters able to escape killing.

Publisher URL: http://doi.org/10.1128/AAC.01596-17

DOI: 10.1128/AAC.01596-17

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.